Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Infectious Disease
•
General Infectious Disease
In what situations would you treat a corynebacterium positive blood culture as a true pathogen compared to a contaminant?
Related Questions
For a patient on appropriate treatment for invasive aspergillosis, how do you determine if and when it is acceptable to reintroduce a TNF inhibitor that likely contributed to their acquisition of the infection but is considered essential for control of their inflammatory condition?
Do you treat complicated pneumonia with a drained empyema longer if Streptococcus anginosus is cultured, either in isolation or with other organisms, compared to cases in which it is not?
When do you recommend limited or targeted respiratory pathogen testing versus a full respiratory pathogen panel in a patient presenting with URI symptoms?
Do you routinely recommend suppressive antibiotic therapy for patients with spinal hardware infections who have undergone surgical debridement with retention of hardware?
What specific clinical signs or epidemiological indicators do you prioritize for early identification of Bartonella quintana infection?
How have the results of the BALANCE trial, which demonstrated the noninferiority of 7 days of antibiotics compared to 14 days for non-S. aureus bloodstream infections, influenced your practice?
In a patient with vaginal itching and a vaginal swab with a positive Candida glabrata NAAT, what is your first-line therapy?
Do you switch to an alternative agent for C difficile colitis for a patient with suspected infection and positive testing who continues to have >3 watery bowel movements daily despite multiple days of oral vancomycin treatment?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
What role could emerging technologies, such as antimicrobial coatings or biofilm-disrupting agents, play in reducing the incidence of CIED infections?
